Journal of Clinical Oncology
Articles in this Issue
Preliminary efficacy of GFH375 in patients with advanced cholangiocarcinoma or colorectal cancer harboring KRAS G12D mutation.
3008 Background: Kirsten rat sarcoma (KRAS) G12D is the most prevalent RAS mutation in human cancers, accounting for 10.6-...
PRiMAL (precision randomized clinical trial comparing MTB assisted care to usual care): Quality of life analysis in patients with newly diagnosed non-small cell lung cancer (NSCLC).
1574 Background: Precision medicine—tailoring cancer treatment to a tumor’s genomic profile—is more effective and less tox...
Analyzing trends in multimorbidity-related mortality among patients with lung cancer and hypertensive diseases: A 25-year nationwide analysis.
e20694 Background: Multimorbidity, defined as the coexistence of two or more chronic conditions, poses major challenges to...
Survival implications of context-dependent oncogenic <i>PIK3CA</i> mutations in HNSCC.
6114 Background: Head and neck squamous cell carcinoma (HNSCC) is a heterogenous disease that generally lacks clinically u...
Evaluating tumor genomics and FES-PET in estrogen receptor–positive (ER+) breast cancer (BC).
e15072 Background: 18 F-fluoroestradiol positron emission tomography (FES-PET) is a highly specific im...
Firmonertinib combined with cisplatin/carboplatin plus pemetrexed as neoadjuvant therapy in resectable stage II-IIIb <i>EGFR</i> -mutated non–small cell lung cancer: A single-arm, single-center, open-label phase II study.
8058 Background: For patients with resectable, locally advanced EGFR-mutated NSCLC, traditional neoadjuvant chemotherapy y...
Natural language processing chatbot and continuous activity monitoring in a phase II randomized trial: Impact on hospitalizations and quality of life.
12132 Background: Toxicities associated with concurrent chemoradiotherapy (CRT) can lead to hospitalizations and impaired...
Vitiligo and alopecia areata as complementary human models of immune-mediated melanoma protection: A systematic review and meta-analysis.
e21547 Background: Durable immune-mediated tumor surveillance is central to cancer prevention and long-term disease contro...
Can functional tumor profiling lead to superior care within standard of care?: A meta-analysis of randomized controlled trials.
e23092 Background: The adoption of novel drugs or therapies is generally dependent on randomized controlled trials (RCTs),...
Efficacy and safety of larotrectinib in patients with <i>TRK</i> fusion lung cancer: An updated analysis.
8618 Background: NTRK gene fusions are oncogenic drivers in various tumor types, including lung cancer...
Comparative effectiveness of first-line FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients aged ≧ 75 years with metastatic pancreatic cancer: A multinational real-world study.
e16385 Background: Randomized trials supporting first-line chemotherapy for metastatic pancreatic cancer have systematical...
USP43 downregulation as driver of acquired resistance to dabrafenib and trametinib in melanoma via the HIF1A-PDK1 axis-mediated oxidative phosphorylation.
e21517 Background: Acquired resistance to combined BRAF and MEK inhibition (Dabrafenib+Trametinib) limits long-term surviv...
Comparative outcomes of red blood cell transfusion versus erythropoiesis-stimulating agents in lung cancer patients with chemotherapy-induced anemia: A real-world analysis.
e20781 Background: Chemotherapy-induced anemia affects up to 80% of lung cancer patients and is associated with significan...
Exposure–response (E–R) analyses of efficacy and safety with raludotatug deruxtecan (R-DXd), a CDH6-directed antibod-drug conjugate (ADC), to inform dose selection for phase (Ph) 3 development in platinum-resistant ovarian cancer (PROC).
5570 Background: R-DXd, an ADC, comprises a humanized cadherin 6 (CDH6) IgG1 monoclonal antibody attached to a topoisomera...
Machine learning risk stratification in a US-based database to identify subgroups of patients with PD-L1-high NSCLC who benefit from adding chemotherapy to pembrolizumab.
e20523 Background: First-line treatment options for advanced non-small cell lung cancer (aNSCLC) with PD-L1 TPS ≥50% inclu...
Differential clinical and economic signatures of CAR T-cell therapy in DLBCL across demographic and payer strata: A national analysis.
7064 Background: Chimeric antigen receptor (CAR) T cell therapy has revolutionized care for relapsed/refractory diffuse la...
Mortality trends for co-occurring colon carcinoma and metabolic syndrome in the United States: A CDC WONDER analysis, 1999-2020.
e15614 Background: Colon carcinoma remains a leading cause of cancer morbidity and mortality in the United States, with pe...
Differential clinical and economic signatures of CAR T-cell therapy in multiple myeloma across demographic and payer strata: A national analysis.
e19537 Background: Chimeric antigen receptor (CAR) T cell therapy is a paradigm shifting modality for relapsed/refractory...
Dysphagia-associated inpatient risk phenotypes and mortality in hospitalized head and neck cancer: A national analysis.
11085 Background: Dysphagia is common in patients with head and neck cancer (HNC) but is often viewed as a quality-of-life...
Germline pathogenic variants in early-onset colorectal cancer and limitations of tumor-based screening.
e15719 Background: In the United States, the incidence of early-onset colorectal cancer (EOCRC) is increasing, yet real-wo...
Knowledge and practice toward hereditary lung cancer in Brazil: A GBOT (Grupo Brasileiro de Oncologia Torácica) national survey.
e20780 Background: Non–small cell lung cancer (NSCLC) in never smokers represents 10–25% of cases and shows distinct epide...
Trends in cancer drug revenue retained by providers under buy-and-bill reimbursement, 2010-2024.
11032 Background: Cancer care providers, including physician offices and hospitals, retain “markup” fees on clinician-admi...
Body mass index (BMI) and overall survival (OS) among Hispanic patients treated with immune checkpoint inhibitors (ICIs).
11171 Background: Prior studies have suggested improved OS among cancer patients receiving ICIs with higher BMI, despite o...
Patient-reported quality of life and breast specific symptoms among long term survivors of breast cancer in India: A cross-sectional analysis using EORTC QLQ C30 and QLQ BR42.
e12743 Background: Understanding how cancer therapies affect day to day living requires listening to patients, not just me...
Prognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC).
4600 Background: BC has high recurrence risk despite curative intent surgery and perioperative therapy. As ctDNA guided st...